about
An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cellsTargeting the translational machinery as a novel treatment strategy for hematologic malignanciesThe treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulationRecent advances in the discovery of small molecule mTOR inhibitors.Intracellular parasitism with Toxoplasma gondii stimulates mammalian-target-of-rapamycin-dependent host cell growth despite impaired signalling to S6K1 and 4E-BP1.Rapamycin selectively reduces the association of transcripts containing complex 5' UTRs with ribosomes in C4-2B prostate cancer cells.PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer CellsHydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells.Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt LymphomaProfiling of the fetal and adult rat liver transcriptome and translatome reveals discordant regulation by the mechanistic target of rapamycin (mTOR)Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.The Enigma of Rapamycin Dosage.The effect of rapamycin on DNA synthesis in multiple tissues from late gestation fetal and postnatal rats4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro.Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanismGNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells.Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.Targeted therapy for sarcomas.MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.Past, present and future of therapies in pediatric sarcomas.Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies.Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma.Choice of stent and outcomes after treatment of drug-eluting stent restenosis in highly complex lesions.Metformin induces degradation of mTOR protein in breast cancer cells.De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR.Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.HPV-16 E7 expression up-regulates phospholipase D activity and promotes rapamycin resistance in a pRB-dependent manner.
P2860
Q33709439-1DCA2606-00E3-4734-B4A8-3F136495D68AQ33747291-428FEEE9-5933-42A0-A1E8-045B483C7224Q33816583-D64E77A9-BA78-4EB8-BED8-4ADD4E28DBEAQ33852446-C5FE0307-C78C-4DC9-9398-BA1970A6E154Q33894468-64C77CF2-FBA3-4169-8E36-D297355056EDQ34033097-FD4E6FA0-E4E3-405B-8E40-EB289654C1E8Q34164683-B6223A24-2F14-4B35-9D2E-C227027C54A4Q34173253-F695B61F-8887-401D-9284-4DC0C9AEF59FQ34200875-A6D88F97-469E-4E53-A7EF-D45FA6071CF3Q35670917-CBD359FD-3673-4BFE-ABF7-5FC0608EEA0FQ35680679-E4B2F882-451A-4666-A036-3A614825EC8EQ35696506-19765D9D-B1FF-4117-A1FC-0BF12732232FQ35817942-3357F0E7-6AC6-479A-A410-A1BB86939237Q35993104-7E82ADB6-BBC1-4CF2-82DC-727B03CE1741Q36664900-3808C097-8BC7-4DF9-9FF8-24F48D9924D2Q36842368-F860F846-37FD-4226-BB4E-C67D19F3044CQ36965860-87E6DD47-5683-449A-A6A6-FF461967E173Q36992167-00B4CE1D-7EAD-4E4E-876E-3D502E978C08Q37001348-1B110926-9717-4585-BAD0-FA3901DAF9C8Q37058301-1FFB1933-C2FA-4377-8923-DDB6874359FDQ37373332-6FCF249E-3D73-4943-A159-D803AB0A0A76Q37565435-4893917A-D061-48F2-982D-114F7AC21091Q37655450-395EA0E1-787A-4AE4-A017-F93C914CADD7Q37688200-93C02576-FCAA-4E70-AE29-424BCC40B7A4Q37690245-E74581A1-DF08-4C61-B15B-4634EC0C1921Q37725915-2600B59F-95C4-4627-A865-E104825A492FQ37837732-2BC28C2E-3CF5-4022-BF8D-DCAC0BA5D75FQ38796904-627022FC-DE10-4A3A-87D1-ACC1A1B1F64BQ39318989-63060B53-8F08-487B-B875-E7BA6F786F6FQ39475114-80BED531-DC29-4B3B-A757-4A24D80E2280Q39628078-829AE8E0-07A4-4266-8221-849C09AC9ED7Q42364561-B006057B-3DF9-4FC0-B563-D91ED435DF21Q42524659-692B8FA7-512E-4177-80B5-7507973C0810Q42579657-3DD856E2-385C-4E75-904D-F8045C5711E2Q51554260-6D701E1C-C1DA-4FD4-A0F2-C9D8D9141D1CQ55223142-F0E8E7D7-CC15-454F-ABD0-5EC1FDB42CCA
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Predicted mechanisms of resistance to mTOR inhibitors.
@ast
Predicted mechanisms of resistance to mTOR inhibitors.
@en
type
label
Predicted mechanisms of resistance to mTOR inhibitors.
@ast
Predicted mechanisms of resistance to mTOR inhibitors.
@en
prefLabel
Predicted mechanisms of resistance to mTOR inhibitors.
@ast
Predicted mechanisms of resistance to mTOR inhibitors.
@en
P2093
P2860
P921
P356
P1476
Predicted mechanisms of resistance to mTOR inhibitors.
@en
P2093
P J Houghton
R T Kurmasheva
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603353
P407
P577
2006-09-05T00:00:00Z
2006-10-23T00:00:00Z
P5875
P6179
1030175427